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In recent years, significant progress has been made in new
therapeutic approaches to breast cancer, particularly in pa-
tients with HER2-positive and HER2-negative/hormone recep-
tor-positive (HR+) breast cancer. In the case of HER2-positive
tumours, these approaches have included, in particular, treat-
ment with pertuzumab, T‑DM1, neratinib and, soon, also tu-
catinib and trastuzumab deruxtecan (neither of which has yet
been authorised in Europe). In patients with HER2−/HR+
breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor al-
pelisib are of particular importance. Further novel therapies,
such as Akt kinase inhibitors and oral SERDs (selective estro-
gen receptor down regulators), are already being investigated
in ongoing clinical trials. These therapeutic agents are not
only being introduced into curative, (neo-)adjuvant therapeu-
tic settings for HER2-positive tumours; a first favourable study
on abemaciclib as an adjuvant therapy has now also been
published. In patients with triple-negative breast cancer, after
many years of negative study results with the Trop-2 antibody
drug conjugate (ADC) sacituzumab govitecan, a randomised
study has been published that may represent a significant
therapeutic advance. This review describes the latest develop-
ments in breast cancer subsequent to the ESMO Congress
2020.
ZUSAMMENFASSUNG
Bei neuen Therapieansätzen des Mammakarzinoms sind ins-
besondere bei Patientinnen mit HER2-positiven und den
HER2-negativen/hormonrezeptorpositiven (HR+) Mammakar-
zinom in den letzten Jahren deutliche Fortschritte gesehen
worden. Bei HER2-positiven Tumoren muss in dem Zusam-
menhang Pertuzumab, T‑DM1, Neratinib und bald auch Tuca-
tinib und Trastuzumab-Deruxtecan (beide in Europa noch
nicht zugelassen) genannt werden. Bei den Patientinnen mit
HER2−/HR+ Mammakarzinom sind insbesondere die CDK4/6-
Inhibitoren und der PIK3CA-Inhibitor Alpelisib zu nennen.
Weitere, neue Therapien, wie Akt-Kinase-Inhibitoren und ora-
le SERDs (selective estrogen receptor down-regulators), wer-
den bereits in laufenden klinischen Studien untersucht. Nicht
nur bei den HER2-positiven Tumoren halten die Therapien Ein-
zug in die kurative, (neo-)adjuante Therapiesituation, sondern
es wurde nun eine erste positive Studie mit Abemaciclib in der
adjvuanten Situation vorgestellt. Bei Patientinnen mit einem
triple-negativen Mammakarzinom ist nach vielen Jahren von
negativen Studienergebnissen mit dem Trop-2 Antikörper-
Wirkstoff-Konjugat (antibody drug conjugate, ADC) Sacitu-
zumab-Govitecan eine randomisierte Studie veröffentlicht
worden, die einen deutlichen Therapiefortschritt bedeuten
kann. Diese Übersichtsarbeit beschreibt die neuesten Ent-
wicklungen beim Mammakarzinom nach dem ESMO-Kon-
gress 2020.
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Care for patients with breast cancer is complex and incorporates
prevention, early detection, treatment and follow-up. Significant
progress has been made in each of these areas in recent years
[1–9].
Evidence has been accumulating that risk prediction for the
disease can now differentiate relatively well between validated,
genuine risk genes and genes from analytical panels that have no
straightforward association with breast carcinoma. As a result, a
major study to clarify the findings has been published.
The speed with which new therapies are being introduced is
accelerating significantly. For example, the effectiveness of the
antibody drug conjugate sacituzumab govitecan was recently
demonstrated in a randomised study for triple-negative breast
cancer (TNBC), and studies on the tyrosine kinase inhibitor tucati-
nib and the antibody drug conjugate trastuzumab-deruxtecan are
currently being conducted for HER2-positive breast cancer. In pa-
tients with HER2−/HR+ breast cancer, new targeted combinations
and also new anti-oestrogenic agents are being tested following
the introduction of CDK4/6 inhibitors and the PI3K inhibitor alpe-
lisib.470 Lux MP et al.Significant developments in healthcare have also been made in
the field of digital medicine, partly as a result of the COVID 19
pandemic. This review summarises and reflects upon such recent
developments, as presented in scientific publications and at re-
cent congresses such as the ESMO Congress 2020.Neoadjuvant Therapy
Immune therapies in neoadjuvant therapy
The KEYNOTE-522 study, a large randomised neoadjuvant study,
showed that supplementation of therapy with pembrolizumab in
triple-negative breast cancer resulted in an improvement in the
pathological complete remission rate (pCR) from 51.2% to 64.8%
[10–12].
Similar results have now been reported with atezolizumab
[13]. The IMpassion031 study included patients with early TNBC
whose primary tumour was at least 2 cm in size. Another require-
ment was that patientsʼ PD‑L1 status had to be determinable.
However, it did not have to be positive. Patients were treated with
chemotherapy of 12 cycles of weekly nab-paclitaxel followed by
dose-dense therapy with biweekly doxorubicin (60mg/m2) com-Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 469–480 | © 2021. The author(s).
bined with cyclophosphamide (600mg/m2). The patients also re-
ceived atezolizumab at 840mg or placebo every 2 weeks. After
surgery, therapy with atezolizumab was completed with 11
three-weekly cycles of 1200mg in the atezolizumab arm. A total
of 333 patients were randomised and 307 patients underwent
surgery. The pCR rate in the placebo arm was 41.1%, while the
pCR rate in the atezolizumab arm was 57.6% (16.5% difference,
95% CI: 5.9–21.7%, p = 0.0044). In the subgroup analysis based
on PD‑L1 status (positive if at least 1% of immune cells exhibited
staining), pCR rates of 68.8% (atezolizumab arm) and 49.3%
(placebo arm) were observed in the group with positive PD‑L1 sta-
tus (difference 19.5%, 95% CI: 4.2–34.8%). In patients with PD‑L1-
negative breast cancer, pPCR rates of 47.4% (atezolizumab arm)
and 34.4% (placebo arm) were achieved (difference 13.3%,
95% CI: − 0.9–27.5%) [13]. Survival parameters (event-free surviv-
al, disease-free survival and overall survival) with a median obser-
vation period of about 20 months were also reported. On the ba-
sis of very few events and wide confidence intervals, the atezolizu-
mab arm showed a numerical (statistically non-significant) advan-
tage over the placebo arm. No new side-effect profiles were re-
ported. Thus, in the neoadjuvant setting in TNBC, two random-
ised trials, one on pembrolizumab [11] and the other on atezolizu-
mab [13], have now shown a significant improvement in pCR rate.
▶ Table 1 provides an overview of the neoadjuvant, random-
ised trials that are investigating therapy with a PD1 or PD‑L1 inhib-
itor.Adjuvant Treatment of Patients
with Breast Cancer
The last time a novel anti-hormonal therapy was introduced in the
adjuvant setting was almost 20 years ago. At that time, findings of
an absolute difference in disease-free survival of 2% comparing
5 years of anastrozole to 5 years of tamoxifen [14] led in 2002 to
authorisation in the USA. The hazard ratio in the initial analysis
with a median follow-up period of 33.3 months was 0.83
(95% CI: 0.71–0.96) [14]. The hazard ratio in the final analysis with
a 10-year follow-up was 0.86 (95% CI: 0.76–0.97) for the first
5 years (total population) and 0.83 (95% CI: 0.72–0.95) for hor-
mone receptor positive tumours [15]. It should be noted that the
ATAC study included some patients with unknown hormone re-
ceptor status (approximately 8%) [14]. Beyond this first study on
the use of an aromatase inhibitor in the adjuvant setting, mention
should likewise be made of the large number of other studies in
the adjuvant setting that have also investigated letrozole and
exemestane [16,17]. Regardless of the successes achieved by the
introduction of aromatase inhibitors almost 20 years ago, the ma-
jority of deaths in breast cancer patients occur in the HR+/HER2−
group of patients, as these make up the largest percentage of all
breast cancers. Improving the treatment of these patients would
have a major impact on the overall population. Following the
promising data on CDK4/6 inhibitors (CDK4/6i) in the metastatic
setting, trials have also been initiated for all three CDK4/6i in the
adjuvant setting [18–22]. The first two of these studies (PALLAS
and MonarchE) have now been presented at the ESMO Congress
2020 [23,24].Lux MP et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 469–480 | © 2021. The aPALLAS
The PALLAS study included 5760 patients who had to fulfil the fol-
lowing criteria (selection):
▪ HR+/HER2−
▪ UICC stage II or III
▪ Completion of all primary therapy options
▪ Primary diagnosis not more than 12 months ago
▪ Initiation of adjuvant endocrine therapy (ET) less than 6months
previously
Most patients had a UICC stage of IIB (33.4%) or III (48.7%). A very
high percentage had received chemotherapy (82.6%). The per-
centage of patients with a negative nodal status was 13.0% [23].
Patients were treated with endocrine therapy (ET) ± palbociclib
for 2 years. Afterwards, the scheduled endocrine therapy is com-
pleted as a monotherapy.
The results of this study were negative. In an interim analysis, a
“futility” analysis was performed after the 351 events pre-spec-
ified to terminate the study. At a median follow-up period of
23.7 months, the hazard ratio was 0.93 (95% CI: 0.76–1.15) with
invasive relapse-free 3-year survival rates (iDFS) of 88.2% (palbo-
ciclib + ET arm) vs. 88.5% (endocrine monotherapy arm).
MonarchE
The MonarchE study investigating abemaciclib yielded a different
result. Patients were included in this study if they had more than
3 affected lymph nodes or 1–3 affected lymph nodes and a tumour
size of at least 5 cm, a grade 3 tumour or a Ki-67 index of ≥ 20%.
Again, most patients in this study had a UICC stage of IIB
(13.8%) or III (approx. 72%). Patients received standard-of-care
adjuvant endocrine therapy with or without abemaciclib for
2 years. At the time of the first interim analysis, invasive disease-
free survival was assessed after 323 events and a median follow-
up time of 15.5 months. The analysis revealed a significant advan-
tage in favour of the combination therapy. The hazard ratio was
0.72 (95% CI: 0.56–0.92), with 2-year invasive relapse-free surviv-
al rates of 92.2% and 88.7%, respectively. ▶ Fig. 1 presents the Ka-
plan-Meier curve for the results. ▶ Fig. 2 shows a comparison of
the Kaplan-Meier curves of the ATAC study [14] and the MonarchE
study [25] at the time of initial publication.
PENELOPE‑B study
The PENELOPE‑B study [26] – initially reported to be negative via a
press release – is another adjuvant CDK4/6i study. This study in-
cluded patients who did not achieve pCR after neoadjuvant che-
motherapy and had an unfavourable prognostic profile based on
a clinical-pathologic stage – estrogen/grade (CPS‑EG) score [27].
PENELOPE‑B included patients who had a CPS‑EG score of 3 or
higher or a score 2 and ypN+ disease. The PENELOPE‑B study was
the only placebo-controlled study, and therapy with palbociclib
lasted 1 year. The final analysis of the study has now been pub-
lished [28].
NATALEE study
One study still open for recruitment is the NATALEE study [19].
This study is evaluating ribociclib therapy over 3 years in a popula-
tion of patients at a lower and higher risk of relapse. The number471uthor(s).
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As yet unpublished As yet unpublished [59]
* Statistically not significant in accordance with the pre-specified analysis plan including interim analyses
GebFra Science | Reviewof patients was recently increased from approximately 4000 pa-
tients [29] to 5000 patients [19]. In the PENELOPE‑B and Mon-
archE studies patients were administered a CDK4/6 inhibitor for
one year or two years respectively. The NATALEE study, in con-
trast, will provide information on a longer duration of therapy of
three years. Another study, the ADAPTcycle study, is being con-472 Lux MP et al.ducted in Germany, comparing adjuvant chemotherapy with en-
docrine-based therapy (2 years of ribociclib), while the ADAPTlate
study is investigating the use of abemaciclib 2–6 years after initial
diagnosis.
▶ Table 2 compares the inclusion and exclusion criteria of the




















Abemaciclib + ET 2 808
p = 0.01


















































▶ Fig. 1 Remote metastases-free survival in the MonarchE study (data from [24]).Treatment of Patients
with Metastatic Breast CancerImmunotherapies IMpassion131, IMpassion130,
KEYNOTE-355
The PD‑L1 inhibitor atezolizumab has now been authorised for pa-
tients with advanced triple-negative breast cancer following the
findings of the IMpassion130 trial, which revealed an improve-
ment in progression-free survival and overall survival in patients
with immune cell (IC) PD‑L1-positive tumours [30,31]. Similarly,
the KEYNOTE-355 study showed that the addition of pembrolizu-
mab to chemotherapy significantly improved progression-free
survival. In the USA, pembrolizumab has already been authorised
for this indication.
The IMpassion130 study selected nab-paclitaxel as combina-
tion therapy for atezolizumab. Various chemotherapies (nab-pac-
litaxel, paclitaxel, or gemcitabine and carboplatin) were permitted
in the KEYNOTE-355 study. Based on a subgroup analysis of com-
bination partners, the KEYNOTE-355 study found no differences
between the chemotherapy options with which pembrolizumab
was combined.
The IMpassion131 study [32] investigated a study population
similar to that of IMpassion130, but whose subjects were random-
ised to paclitaxel + atezolizumab or to paclitaxel monotherapy
(+ placebo) at a 2 :1 ratio [32]. A total of 651 patients were re-
cruited, of which 292 had tested positive for PD‑L1 (immune cells
positive in ≥ 1%). Neither in the PD‑L1-positive population nor inLux MP et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 469–480 | © 2021. The athe overall population was a benefit observed for progression-free
survival or overall survival [32].
It has been suggested that the lack of effect of atezolizumab in
combination with paclitaxel may have been due to cortisone,
which was co-administered during therapy with soluble paclitaxel.
Ultimately, however, such an explanation must be regarded as
speculative. It is known that different chemotherapies have differ-
ent effects on the immune system [33] and also interact differ-
ently with PD1/PD-L1 inhibitors [34].
Convincing data on sacituzumab govitecan
in TNBC patients (ASCENT study)
There have already been significant therapeutic successes in the
field of antibody drug conjugates (ADC) in HER2-positive patients
[35–37]. An epithelial glycoprotein (Trop-2) that is expressed by
breast cancer cells and is associated with a poorer prognosis has
now been identified in patients with triple-negative breast cancer,
as well as potentially in the future in other subtypes [38,39]. The
ADC sacituzumab govitecan acts on this target, with SN-38, a
cytostatic agent similar to irinotecan but highly potent, as a pay-
load. In the USA, sacituzumab govitecan has already been author-
ised on the basis of positive data from the early therapeutic study
[40].
ASCENT is a randomised phase III study in which TNBC patients
with ≥ 2 prior chemotherapies are treated with either sacituzu-
mab govitecan or a chemotherapeutic treatment of physician
choice [60]. A total of 529 patients were included. The study was
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▶ Fig. 2 Comparison of disease-free survival in the ATAC study with a 33.3-month follow-up and invasive disease-free survival in the MonarchE
study with a 15-month follow-up (data from [24]).
GebFra Science | ReviewAll included patients had previously received a taxane, approx.
7–8% had received a PARP inhibitor and approx. 26–29%, a PD1/
PD-L1 inhibitor.
A clear difference was observed between the randomised arms
of the study. Patients receiving chemotherapy of physician choice
progressed at a median of 1.7 months (95% CI: 1.5–2.6), while pa-
tients receiving treatment with sacituzumab govitecan did not
progress until 5.6 months (95% CI: 4.3–6.3). The corresponding
hazard ratio was 0.41 (95% CI: 0.32–0.52, p < 0.0001). A clear dif-
ference in overall survival was also observed. The median time to
death for patients in the chemotherapy arm was 6.7 months
(95% CI: 5.8–7.7), while the median time to death for patients in474 Lux MP et al.the sacituzumab-govitecan arm was 12.1 months (95% CI 10.7–
14.0). The hazard ratio was 0.48 (95% CI: 0.38–0.59, p < 0.0001).
▶ Fig. 3 presents the Kaplan Meier curves.
The most common side effects (all grades) were neutropoenia
(63%), anaemia (34%), vomiting (29%), diarrhoea (59%) and fa-
tigue (45%). However, these led in only 4.7% of patients to prema-
ture discontinuation of therapy.
Overall survival analysis of the SOLAR-1 study
The PI3K inhibitor alpelisib was recently approved after it had
been shown to improve median progression-free survival from
5.7 months to 11 months in patients with HER2−/HR+ metastaticUpdate Breast Cancer… Geburtsh Frauenheilk 2021; 81: 469–480 | © 2021. The author(s).
▶ Table 2 Comparison of inclusion and exclusion criteria of (post-)adjuvant therapy studies with CDK4/6 inhibitors.
Criterion PALLAS MonarchE NATALEE PENELOPE‑B












T1–T4 and N1 with
▪ ≥ 4 ipsilateral positive axillary
lymph nodes
▪ 1–3 ipsilateral positive axillary
lymph nodes and at least
one of the following criteria:
– G3
– tumour size ≥ 5 cm








▪ T3 N0 or T2 N0 with
– G3 or
– G2 and Ki-67 ≥ 20% or oncotype DX
≥ 26, PAM50 high risk, MammaPrint
high risk, EndoPredict high risk
≥ ypT1 or
≥ ypN1





HR+/HER2− HR+/HER2− HR+/HER2− HR+/HER2− and CPS‑EG
score of ≥ 3 or CPS‑EG









Randomisation within 16 months
of surgery and at least 21 days
after the last chemotherapy and
at least 14 days after the final
radiotherapy
Randomisation within 18 months of ini-
tial diagnosis and nomore than 6months
after the commencement of endocrine
therapy or “high risk” on the basis of
a gene expression test (Onkotype DX,
Prosigna, MammaPrint or EndoPredict)
Randomisation within
16 weeks of surgery
or maximum 10 weeks
after completion
of radiotherapy
ECOG ≤ 1 ≤ 1 ≤ 1 ≤ 1
ECG QTcF < 480ms No limit specified QTcF < 450ms QTcF < 480ms
ALT = alanine aminotransferase, AST = aspartate aminotransferase, ECG = electrocardiography, GFR = glomerular filtration rate,
INR = International normalized ratio, QTcF = QT interval corrected with the Fridericia formula, ULN = upper limit of normalbreast cancer and with a somatic PIK3CAmutation who had previ-
ously received endocrine therapy (hazard ratio: 0.65, 95% CI:
0.50–0.85) [41]. Data on overall survival have now been reported
revealing 181 patients died (out of a total of 341 patients) [42].
Even if the addition of alpelisib to fulvestrant improved overall
survival from 31.4 months (95% CI: 26.8–41.3) to 39.3 months
(95% CI: 34.1–44.9), this difference was not statistically signifi-
cant (HR = 0.86, 95% CI: 0.64–1.15, p = 0.15). A subgroup analysis
suggested that a significant part of the effect was attributable to
patients with a lung or liver metastasis. In this subgroup of 190 pa-
tients, the difference in median overall survival was almost
15 months (37.2 vs. 22.8 months, HR = 0.68, 95% CI: 0.46–1.00)
[42].
As testing is one of the prerequisites for alpelisib therapy, test-
ing and methodology are increasingly a focus of interest. Muta-
tions can be analysed from DNA extracted from paraffin-em-
bedded tumours as well as from circulating DNA (ctDNA). Accord-
ing to its protocol [41], the SOLAR-1 study tested for the following
mutations: C420R, E542K, E545A, E545D (only 1635G>T), E545G,
E545K, Q546E, Q546R, H1047L, H1047R and H1047Y. Alpelisib is
likely to be effective against tumours with a number of other dif-
ferent mutations, but prospective data on this should be awaited.
It should be noted, however, that mutations other than those
mentioned are very rare, as the vast majority of mutations in PIK3-
CA are restricted to three so-called hotspots.Lux MP et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 469–480 | © 2021. The aFocus on quality of life
Quality of life is a particular focus of treatment for patients with
advanced cancer. If possible, therapy should have a positive effect
on quality of life. At a minimum, the patientʼs quality of life should
be maintained and not worsened. This can be achieved by suc-
cessful symptomatic treatment or by delaying progression. It has
been established that progression is associated with a deteriora-
tion in quality of life [43]. Treatment with novel substances is
often associated with an intensification of therapy or with the in-
troduction of an additional concomitant drug. Critical assessment
of quality of life is therefore important. Several analyses on quality
of life have been published on CDK4/6 inhibitors that are widely
used in early lines of therapy in advanced breast carcinoma [44].
Most such analyses revealed combination therapy and endocrine
monotherapy were associated with similar quality-of-life scores
[45–47], while one study revealed a benefit for combination ther-
apy [48]. Recently, a pooled analysis of all ribociclib studies was
performed [49]. Reviewing all studies, this analysis showed that
combination therapy can significantly delay deterioration in qual-
ity of life. In subgroup analyses, which generate hypotheses, the
effect was greatest in patients between 45 and 60 years of age
and in patients with visceral metastases [49].
For patients with HER2-positive breast cancer who have al-
ready been treated with all standard options, further treatment
options with tucatinib and trastuzumab deruxtecan will most
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235 222 166 134 127 104 81 63 54 37 33 24 22 16 15 13 9 8 8 5 3 1 0
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▶ Fig. 3 Progression-free survival (a) and overall survival (b) for randomisation arms in the ASCENT study (SG = sacituzumab govitecan;
TPC = treatment of physicianʼs choice. Data from [60], survival rates were added).
476 Lux MP et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 469–480 | © 2021. The author(s).





















▶ Fig. 4 Perspectives for digital medicine.Europe) [37,50]. Quality-of-life data have recently been published
for the randomised HER2CLIMB study [51]. In this analysis, in
which almost half of all patients had brain metastases, the addi-
tion of tucatinib to trastuzumab and chemotherapy did not result
in any difference in quality of life [51] despite a more unfavoura-
ble side-effect profile [50]. It is worth noting that significant ben-
efits in progression-free survival and overall survival had already
been reported for tucatinib when comparing the randomisation
arms [50].Digital Medicine
Catalysed in part by the COVID-19 pandemic, the prospects for
digital medicine have once again undergone a transformation.
The pandemic has highlighted the obvious advantages of collect-
ing data digitally and providing care to patients, without them
having to physically attend medical appointments in a hospital or
in private practice. However, it was clear even before the pandem-
ic that shifting appointments to monitor therapies and illnesses to
the patientsʼ own homes had the potential to improve the quality
of life of patients and reduce the burden on the healthcare system
[52]. In addition, modern smart sensory systems are enabling pa-
tients to collect medically relevant information [53]. The ability to
record ECG data, conduct blood analyses, monitor activity and
sleep patterns as well as other information via smart phones and
smart watches and to use this information for patient care is
opening up new perspectives in both care and research.
Collecting information about patientsʼ conditions allows
caregivers to communicate with patients about such information
and to analyse the data to gain new insights into patient groups.
Data from private practice and from hospitals can be merged withLux MP et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 469–480 | © 2021. The aother healthcare-related data. Such datasets can be managed and
analysed using machine learning to conduct outcome-oriented
research. The findings could enable compliance with guidelines
and improve the information provided to patients, patient care,
home-based care and medical research in equal measure.
▶ Fig. 4 illustrates a possible network of this type.Outlook
Some of the studies presented in this review are relevant to clini-
cal practice; they either describe therapies that for the first time
are clearly effective in disease settings where no effective thera-
pies previously existed (sacituzumab govitecan in patients with
pretreated, advanced TNBC), or they answer specific issues of par-
ticular interest to clinicians. Thus, the issue as to whether atezoli-
zumab can also be successfully combined with paclitaxel – dis-
proved by the IMpassion131 study – has been resolved for the
time being. Atezolizumab should still be combined with nab-pac-
litaxel. The IMpassion031 study has now resulted in data from a
second, larger study in the neoadjuvant therapeutic setting in-
volving checkpoint blockade. It remains to be seen how rapidly
these therapies can be granted authorisation. Such authorisation
would require demonstration of a clear benefit with regard to the
increased rate of side effects described above.
Finally, new methods of care, such as digital medicine, offer
the prospect that healthcare can increasingly be shifted into the
home. It is hoped that scientific studies will be conducted to es-
tablish the extent to which this will improve patientsʼ quality of
life. To date, the personal contact between doctors and patients
has been the most important factor in establishing good therapy
compliance and trust in the necessary therapeutic measures.477uthor(s).
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